In short
This article discusses a clinical trial investigating the use of imlifidase and immunoglobulin in kidney transplantation for highly sensitized children. The trial aims to evaluate the effectiveness and safety of these treatments in improving transplant success rates for children with end-stage renal disease who have difficulty finding suitable donor kidneys due to their immune system's high sensitivity.
At a glance
- Study Type
- Single-arm, multi-centre clinical trial
- Target Population
- Highly sensitized children (1-17 years) needing kidney transplant
- Main Treatment
- Imlifidase and Immunoglobulin
- Primary Objective
- Evaluate crossmatch conversion with imlifidase treatment
- Key Secondary Objectives
- Assess renal function, antibody levels, graft survival, patient survival
- Follow-up Duration
- Up to 5 years post-transplantation
- Key Inclusion Criteria
- PRA ≥80%, positive crossmatch, end-stage renal disease
- Key Exclusion Criteria
- Previous imlifidase treatment, active infections, recent malignancy
What is IMMUNGLOBULIN?
IMMUNGLOBULIN, also known as immunoglobulin, is a type of medication derived from blood plasma containing antibodies. These antibodies are proteins that help your body fight against infections and diseases. In the context of kidney transplantation, IMMUNGLOBULIN is being studied as a potential treatment to help highly sensitized children receive kidney transplants more successfully.
Medical Conditions Treated
The clinical trial is focusing on using IMMUNGLOBULIN to treat highly sensitized pediatric patients who are waiting for a kidney transplant. Being "highly sensitized" means that these children have developed antibodies against a wide range of potential donor organs, making it very difficult to find a suitable match for transplantation.
Specifically, the trial is looking at patients with:
- End-stage renal disease (ESRD): A condition where the kidneys have stopped working well enough for the patient to survive without dialysis or a kidney transplant.
- Positive crossmatch: This means that the patient's immune system is likely to reject the donor kidney.
- High levels of panel reactive antibodies (PRA): A measure of how sensitized a patient is, with 80% or higher considered highly sensitized.
How IMMUNGLOBULIN Works
IMMUNGLOBULIN is being studied as part of a treatment protocol to help reduce the body's immune response against donor kidneys. The goal is to convert a positive crossmatch (which indicates a high risk of rejection) to a negative crossmatch, potentially allowing for successful transplantation.
In this study, IMMUNGLOBULIN is used in combination with other medications to prepare the patient's immune system for the transplant. It's important to note that this is an experimental approach, and its effectiveness is still being evaluated.
Clinical Trial Details
The clinical trial is designed to evaluate the safety and effectiveness of IMMUNGLOBULIN in combination with other medications for kidney transplantation in highly sensitized children. Some key aspects of the trial include:
- It's a single-arm, multi-centre trial, meaning all participants receive the same treatment.
- The study includes children aged 1 to 17 years.
- The main goal is to see if the treatment can convert a positive crossmatch to negative within 24 hours.
- Researchers will monitor kidney function, survival rates, and potential complications for up to 5 years after transplantation.
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including:
- Age between 1 and 17 years
- Diagnosis of end-stage renal disease
- High sensitization (PRA ≥80%)
- Positive crossmatch against a potential donor kidney
- Previous unsuccessful desensitization attempts or deemed too difficult for successful desensitization
There are also several exclusion criteria, such as previous treatment with imlifidase, certain infections, and ongoing serious medical conditions.
Potential Benefits
If successful, this treatment approach could offer several benefits:
- Increased chances of finding a suitable donor kidney
- Reduced risk of organ rejection
- Improved kidney function after transplantation
- Better long-term survival rates for both the patient and the transplanted kidney
Safety and Side Effects
As with any medical treatment, there are potential risks and side effects. The study will closely monitor participants for:
- Infusion-related reactions
- Infections
- Changes in laboratory test results
- Other adverse events
The safety of IMMUNGLOBULIN and the other medications used in this protocol will be carefully evaluated throughout the study.
Other Medications Used in the Study
In addition to IMMUNGLOBULIN, the study protocol includes several other medications:
- Rituximab: A medication that targets certain immune cells
- Methylprednisolone: A corticosteroid to suppress the immune system
- Anti-human T-lymphocyte immunoglobulin: Another medication to modulate the immune response
These medications work together to prepare the patient's immune system for the transplant and reduce the risk of rejection.